WHO calls for urgent health action across the Eastern Mediterranean - Welcome to the United Nations

HealthThe head of the World Health Organization (WHO) has called for promoting, providing and protecting health in the Eastern Mediterranean region, home to some of the world’s top humanitarian crises such as Sudan, Yemen and the Occupied Palestinian Territory. Tedros Adhanom Ghebreyesus was speaking on Wednesday to health leaders and senior officials attending the WHO regional committee meeting underway in Cairo, Egypt. “Over the past year, Member States have continued to advance the health and wellbeing of their people, often under the most difficult circumstances,” he said in remarks on the annual report for the region, which spans 22 countries and territories.

Among cancer patients, the high financial cost of cancer care is a prevalent problem. This financial burden is also associated with potentially harmful behavioral strategies that patients might use to cope with costs, such as delaying or forgoing treatment and skipping medications. Collectively, researchers refer to this impact as financial toxicity.

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.